Nexalin Technology
NXL | NASDAQ
$1.56
+$0.08 (+5.41%)
At close: Nov 16, 2026, 4:00 PM ET
$1.54
-$0.02 (-1.28%)
After-hours:
Nov 16, 2026, 6:00 PM ET
Nexalin Technology Company Profile
Company profile explainedCompany Profile
Nexalin Technology, Inc. operates as a medical device firm specializing in the creation and advancement of neurostimulation therapies for mental health conditions in both the United States and China. The company commercializes its primary product, the Nexalin Device, which provides a non-invasive and drug-free treatment for anxiety and insomnia. This device functions by emitting a proprietary frequency-based waveform designed to elicit a beneficial response from mid-brain structures associated with various psychological disorders. Furthermore, Nexalin Technology is currently developing "Generation 2," a new medical device undergoing clinical trials. This future product aims to address a broader spectrum of health issues, including opiate addiction, persistent pain, Alzheimer's disease, and dementia. The company was founded in 2021 and has its headquarters in Houston, Texas.
Key Executives
| Name | Position |
|---|---|
| Mark White | President, Chief Executive Officer & Director |
| Justin Van Fleet | Chief Financial Officer |
| Carolyn Shelton | Executive Vice President of Clinical, Quality & Regulatory Affairs |
| David Owens | Chief Medical Officer, Member of Scientific Advisory Board & Director |
| John Patrick Claude | Co-Founder and Director of Engineering & Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 27, 2026 | PRE 14A | Filing |
| Oct 15, 2026 | EFFECT | Filing |
| Oct 08, 2026 | S-1/A | [Amend] Filing |
| Oct 01, 2026 | 8-K | Current Report |
| Oct 01, 2026 | 8-K | Current Report |
| Sep 28, 2026 | 8-K | Current Report |
| Sep 22, 2026 | S-8 | Filing |
| Sep 03, 2026 | S-1 | Filing |
| Sep 03, 2026 | SC 13D | Filing |
| Sep 02, 2026 | 8-K | Current Report |
Nexalin Technology
| Country | United States |
| IPO Date | Sep 16, 2022 |
| Industry | Medical - Devices |
| Sector | Healthcare |
| Employees | 8 |
| CEO | Mark White |
Contact Details
1776 Yorktown Houston,
Texas 77056 United States
Stock Details
| Ticker Symbol | NXL |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001527352 |
| CUSIP Number | 65345B300 |
| ISIN Number | US65345B3006 |
| SIC Code | 3845 |
Add to Watchlist
Select watchlists to add or remove NXL